Four IPOs are scheduled for the week of March 25th. The full IPO calendar here.
Based in New York, NY, Garrison Capital (NASDAQ:GARS) scheduled an $80 million IPO with a market capitalization of $240 at a price range mid-point of $15 for Wednesday, March 27, 2013.
GARS is a Business Development Investment Corp retread that was originally scheduled for October 11, 2011. Then is was scheduled to yield 7.75%. Based on the new SEC filing its indicated payout is 7.55% maximum based on recent financials.
Cancer Genetics (NASDAQ:CGIX)
Based in Rutherford, NJ, Cancer Genetics scheduled a $6.6 million IPO with a market capitalization of $44 million at a price range mid-point of $11, for Thursday, March 28, 2013.
CBIX had scheduled an IPO for the week Wednesday, February 13, 2013 but it was postponed.
CBIX is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer.
Pinnacle Foods (NYSE:PF)
Based in Parsippany, NJ, Pinnacle Foods scheduled a $551 million IPO with a market capitalization of $2.15 billion at a price range mid-point of $19 for Thursday, March 28, 2013.
PF has three divisions: Birds Eye Frozen Foods, Duncan Hines Grocery, and Speciality Foods. Sales for the last three years have been flat, in the $2.4 billion plus range. Gross profit is down 5% for 2012 vs 2011, but adjusted net profit is up to $113 million from $60 million.
Based in Hollywood, FL, NV5 Holdings (NASDAQ:NVEE) scheduled a $6 million IPO with a market capitalization of $22 million at a price range mid-point of $6, for the week of March 25th, 2013. NVEE is a hold-over from last week.
NVEE is a small engineering & consulting company heavily dependent on the public sector.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.